{"id":679,"date":"2025-01-21T13:46:20","date_gmt":"2025-01-21T13:46:20","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solutions&p=679"},"modified":"2025-06-02T14:28:45","modified_gmt":"2025-06-02T14:28:45","slug":"atopic-dermatitis","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/dermatology\/atopic-dermatitis\/","title":{"rendered":"Atopic Dermatitis"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers for researching atopic dermatitis (AD)<\/h2>\n \n\n <\/div>\n
\n

Atopic dermatitis is a chronic recurrent inflammatory skin disease, characterized by intense itching that causes discomfort for the patients. The heterogenicity of the patient population includes different trajectories. Some are transient, some relapse and others may progress to develop other type II inflammatory diseases, such as asthma or allergic rhinitis.<\/p>\n

Did you know?<\/h3>\n
\n
\n
\n
\n
\n
\n
\n

Patients who have atopic dermatitis share characteristics of an increased level of tissue remodeling and immune cell activity. Tissue-specific biomarkers<\/a>, quantifying and monitoring epidermal damage, dermal damage and immune cell activity, provide key advantages when we want to understand the disease mechanisms and complexity of atopic dermatitis and type II inflammation. In fact, tissue-specific biomarkers may fast-track targeted successful treatments.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n <\/div>\n

\n

Publications<\/h3>\n